Prostatype Genomics AB
The answer first
Does Prostatype Genomics beat the market?
No, Prostatype Genomics has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 9% of Nordic stocks
- Quality20
- Value55
- Trend3
No. 163 of 192 in healthcare
Max for seven days
Follow Prostatype Genomics with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Prostatype Genomics
Your first answer is free, no account needed.
Do you own Prostatype Genomics, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Prostatype Genomics and a few more. Free, no card.
Super Stock+45.9%In short
- Prostatype Genomics has fallen 84.2% over the past year, including dividends.
- Overall, Prostatype Genomics ranks better than 9% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 99.9%. The price is 100.0% below its peak now.
What do analysts think of Prostatype Genomics?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 9% of Nordic stocks.
No. 163 of 192 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 169 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.81
- Asset turnoverSales divided by everything the company owns0.03
- Return on equityProfit divided by equity−167.7%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 40 of 194 in healthcareTypical in healthcare: 19Typical in the Nordics: 50
- P/BPrice divided by equity0.8
- P/SPrice divided by sales5.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 185 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−29.2%
- 6 months−81.4%
- 9 months−93.1%
- 12 months−84.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Prostatype Genomics
Prostatype Genomics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Nacka, Sweden.


See the full analysis of Prostatype Genomics.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card